Friday, July 10, 2026

pharma · Diabetes Mellitus, Type 2 · Pharmacokinetic trial

Boehringer Ingelheim

Boehringer Ingelheim is a pharma organization headquartered in Ingelheim am Rhein, DE. Primary therapeutic focus areas include Diabetes Mellitus, Type 2, Pharmacokinetic trial, Obesity, Pulmonary Disease, Chronic Obstruc

Binger Straße, Ingelheim am Rhein, Rhineland-Palatinate 55218, DE HQ
46,699 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Binger Straße, Ingelheim am Rhein, Rhineland-Palatinate 55218, DE
Employees
46,699
Programs
193
Drugs
113
Patents
25
Clinical program

BI 695502

Phase 1 · small molecule · Healthy

BI 695502 for Healthy is a Phase 1 program (small_molecule) at Boehringer Ingelheim with 1 ClinicalTrials.gov record(s).

← All Boehringer Ingelheim projects Phase 1 small molecule completed

Internal code 1302.1

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Boehringer Ingelheim
Phase
Phase 1
Modality
small_molecule
Indication
Healthy
Status
completed
Trials
1

Clinical trials